5-tert-butyl-2H-isoindole | 82445-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 5-tert-butyl-2H-isoindole
• CAS: 82445-12-3
• 化学式: C₁₂H₁₅N
• 分子量: 173.258
• InChiKey: KHLSFQTXTVLPRG-UHFFFAOYSA-N

物化性质

• 沸点：
  308.9±11.0 °C(Predicted)
• 密度：
  1.027±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  5-tert-butyl-2H-isoindole 、 1-(4-甲基苯基)-1H-吡咯-2,5-二酮 以83%的产率得到
  参考文献：
  名称：

  KREHER, R. P.;KOHL, N., ANGEW. CHEM., 1984, 96, N 7, 507-508

  摘要：

  DOI：
• 作为产物：
  描述：

  5-tert-Butyl-2-prop-2-ynyl-2,3-dihydro-1H-isoindole 生成 5-tert-butyl-2H-isoindole
  参考文献：
  名称：

  Kreher, Richard P.; Kohl, Norbert, Angewandte Chemie, 1984, vol. 96, # 7, p. 507 - 508

  摘要：

  DOI：

文献信息

• Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239895A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an aryl, heteroaryl or heterocycle (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本文提供了包含式I的补体因子D抑制剂的化合物、使用方法和制备过程，或其药学上可接受的盐或组合物，其中A组上的R12或R13是芳基、杂芳基或杂环（R32）。本文所描述的抑制剂针对因子D并在替代补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所描述的因子D抑制剂能够减少过度激活补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
• Compounds and compositions for inhibition of FASN
  申请人：FORMA Therapeutics, Inc.

  公开号：US10399951B2

  公开（公告）日：2019-09-03

  The present invention relates to compounds and compositions for inhibition of FASN, their synthesis, applications, and antidotes.

  本发明涉及抑制 FASN 的化合物和组合物、其合成、应用和解毒剂。
• Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US10464956B2

  公开（公告）日：2019-11-05

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本发明提供了包含式 I 或其药学上可接受的盐或组合物（其中 A 基上的 R12 或 R13 为芳基、杂芳基或杂环 (R32)）的补体因子 D 抑制剂的化合物、使用方法和制造工艺。本文所述的抑制剂以因子 D 为靶点，在替代补体途径的早期和关键点抑制或调节补体级联，并降低因子 D 调节经典和凝集素补体途径的能力。本文所述的因子 D 抑制剂能够减少补体的过度活化，而补体的过度活化与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• Macrocyclic compounds for treatment of medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US11053253B2

  公开（公告）日：2021-07-06

  Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

  本发明提供了大环补体因子 D 抑制剂、药物组合物及其用途以及制造工艺。所提供的化合物包括式I、式II、式III、式IV、式V、式VI、式VII和式VIII或其药学上可接受的盐、原药、同位素类似物、N-氧化物或分离异构体，可选药学上可接受的组合物。本文所述的抑制剂以因子 D 为靶点，抑制或调节补体级联。
• Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US11084800B2

  公开（公告）日：2021-08-10

  Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

  本发明提供了补体因子 D 抑制剂、药物组合物及其用途以及制造工艺。所提供的化合物包括式I、式II、式III、式IV和式V，或其药学上可接受的盐、原药、同位素类似物、N-氧化物或分离异构体，可选药学上可接受的组合物。本文所述的抑制剂以因子 D 为靶点，抑制或调节补体级联。